share_log

康寧傑瑞製藥-B：2023年報

ALPHAMAB-B: 2023 Annual Report

Hong Kong Stock Exchange ·  Apr 29 05:00
Summary by Moomoo AI
Alphamab Oncology於2023年12月31日結束的年度報告中公布，公司專注於雙特異性抗體和蛋白質工程，旨在全球推廣創新生物製劑。產品管線包括腫瘤單克隆抗體、雙特異性抗體和ADCs，其中一款產品已獲批准，另外三款處於臨床後期階段。公司首個商業化產品為KN035（Envafolimab），但商業化經驗有限。財務摘要顯示，總收入達到人民幣218.8百萬元，較去年有所增長，淨虧損為人民幣210.6百萬元，虧損幅度較去年有所減少。報告期內，公司未建議派發股息，也未有慈善捐贈。公司通過預IPO和IPO後的股票期權計劃激勵員工，並遵守相關公司治理守則，除了董事長與首席執行官的角色未分離外。報告...展開全部
Alphamab Oncology於2023年12月31日結束的年度報告中公布，公司專注於雙特異性抗體和蛋白質工程，旨在全球推廣創新生物製劑。產品管線包括腫瘤單克隆抗體、雙特異性抗體和ADCs，其中一款產品已獲批准，另外三款處於臨床後期階段。公司首個商業化產品為KN035（Envafolimab），但商業化經驗有限。財務摘要顯示，總收入達到人民幣218.8百萬元，較去年有所增長，淨虧損為人民幣210.6百萬元，虧損幅度較去年有所減少。報告期內，公司未建議派發股息，也未有慈善捐贈。公司通過預IPO和IPO後的股票期權計劃激勵員工，並遵守相關公司治理守則，除了董事長與首席執行官的角色未分離外。報告期內，公司未發行可轉換債券或認股權證。股票在香港聯合交易所主板上市。截至最後實際日期，約有4.84%的已發行股份可供IPO後股票期權計劃發行。報告期內，授予了1,350,000股股票期權，880,000股股票期權失效，未有股票期權被取消。此外，公司還採用了IPO後限制性股票獎勵計劃，與股票期權計劃目標相似。報告期內，無與控股股東或其子公司簽訂重大合同，公司及其子公司亦未購買、出售或贖回任何上市證券，且截至2023年12月31日，公司未涉及任何重大訴訟或仲裁，也無重大訴訟或索賠懸而未決。
Alphamab Oncology announced in its annual report ending December 31, 2023, focuses on bi-specific antibody and protein engineering with the aim of promoting innovative biopharmaceuticals globally. The product pipeline includes tumor monoclonal antibodies, binospecific antibodies, and ADCs, of which one product has been approved and the other three are in the post-clinical stage. The company's first commercialized product is KN035 (Envafolimab), but commercialization experience is limited. The financial summary showed that total revenue reached RMB218.8 million, an increase over the previous year, with a net loss of RMB210.6 million, a decrease in the loss margin compared to last year. DURING THE REPORTING PERIOD, THE COMPANY DID NOT PROPOSE TO DISTRIBUTE DIVIDENDS AND NO CHARITABLE DONATIONS. The company incentivizes employees through pre-IPO...Show More
Alphamab Oncology announced in its annual report ending December 31, 2023, focuses on bi-specific antibody and protein engineering with the aim of promoting innovative biopharmaceuticals globally. The product pipeline includes tumor monoclonal antibodies, binospecific antibodies, and ADCs, of which one product has been approved and the other three are in the post-clinical stage. The company's first commercialized product is KN035 (Envafolimab), but commercialization experience is limited. The financial summary showed that total revenue reached RMB218.8 million, an increase over the previous year, with a net loss of RMB210.6 million, a decrease in the loss margin compared to last year. DURING THE REPORTING PERIOD, THE COMPANY DID NOT PROPOSE TO DISTRIBUTE DIVIDENDS AND NO CHARITABLE DONATIONS. The company incentivizes employees through pre-IPO and post-IPO stock option programs and adheres to relevant corporate governance codes, except that the roles of Chairman and CEO are not separated. DURING THE REPORTING PERIOD, THE COMPANY DID NOT ISSUE CONVERTIBLE BONDS OR WARRANTS. The shares are listed on the main board of the Hong Kong Stock Exchange. As of the last effective date, approximately 4.84% of the issued shares are available for post-IPO stock option plans. During the reporting period, 1,350,000 stock options were granted, 880,000 stock options expired and no stock options were canceled. In addition, the company has adopted a post-IPO limited stock reward program, similar to the objectives of the stock options program. DURING THE REPORTING PERIOD, THE COMPANY AND ITS SUBSIDIARIES DID NOT ENTER INTO SIGNIFICANT CONTRACTS WITH THE CONTROLLING SHAREHOLDERS OR THEIR SUBSIDIARIES, NOR DID THE COMPANY AND ITS SUBSIDIARIES PURCHASE, SELL OR REDEEM ANY LISTED SECURITIES, AND AS OF DECEMBER 31, 2023, THE COMPANY WAS NOT INVOLVED IN ANY MAJOR LITIGATION OR ARBITRATION, AND NO SIGNIFICANT LITIGATION OR CLAIMS WERE SETTLED.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more